Compare Stocks: CRBP, DBVT, FDMT, and CTMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$8.86 -16.4%	$9.81	$7.12 ▼ $20.56	$165.42M	2.63	363,448 shs	1.00 million shs
CTMX CytomX Therapeutics	$3.54 -3.0%	$3.49	$1.90 ▼ $8.21	$771.37M	2.14	4.81 million shs	2.05 million shs
DBVT DBV Technologies	$13.44 +1.3%	$14.42	$8.85 ▼ $26.18	$845.11M	-0.95	292,204 shs	89,618 shs
FDMT 4D Molecular Therapeutics	$14.18 -3.1%	$12.60	$6.47 ▼ $16.93	$783.36M	2.74	830,183 shs	493,785 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	-4.33%	-6.03%	+4.23%	+37.66%	+7.18%
CTMX CytomX Therapeutics	-1.62%	-0.54%	+5.49%	+25.43%	+67.43%
DBVT DBV Technologies	-1.48%	-1.12%	-1.56%	-17.27%	+52.02%
FDMT 4D Molecular Therapeutics	-2.27%	+1.95%	+36.09%	+67.78%	+109.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$8.86 -16.4%	$9.81	$7.12 ▼ $20.56	$165.42M	2.63	363,448 shs	1.00 million shs
CTMX CytomX Therapeutics	$3.54 -3.0%	$3.49	$1.90 ▼ $8.21	$771.37M	2.14	4.81 million shs	2.05 million shs
DBVT DBV Technologies	$13.44 +1.3%	$14.42	$8.85 ▼ $26.18	$845.11M	-0.95	292,204 shs	89,618 shs
FDMT 4D Molecular Therapeutics	$14.18 -3.1%	$12.60	$6.47 ▼ $16.93	$783.36M	2.74	830,183 shs	493,785 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	-4.33%	-6.03%	+4.23%	+37.66%	+7.18%
CTMX CytomX Therapeutics	-1.62%	-0.54%	+5.49%	+25.43%	+67.43%
DBVT DBV Technologies	-1.48%	-1.12%	-1.56%	-17.27%	+52.02%
FDMT 4D Molecular Therapeutics	-2.27%	+1.95%	+36.09%	+67.78%	+109.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	362.75% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	236.16% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	260.86% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	108.92% Upside

Current Analyst Ratings Breakdown

Latest CRBP, DBVT, FDMT, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00
8/7/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $35.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
CTMX CytomX Therapeutics	$76.20M	10.12	N/A	N/A	$0.58 per share	6.10
DBVT DBV Technologies	$5.64M	149.84	N/A	N/A	$4.20 per share	3.20
FDMT 4D Molecular Therapeutics	$92.01M	8.51	N/A	N/A	$8.85 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)

Latest CRBP, DBVT, FDMT, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
CTMX CytomX Therapeutics	N/A	9.36	9.36
DBVT DBV Technologies	N/A	3.72	3.72
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CTMX CytomX Therapeutics	67.77%
DBVT DBV Technologies	71.74%
FDMT 4D Molecular Therapeutics	99.27%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	3.50%
CTMX CytomX Therapeutics	3.80%
DBVT DBV Technologies	1.06%
FDMT 4D Molecular Therapeutics	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	18.67 million	18.02 million	Optionable
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable

CRBP, DBVT, FDMT, and CTMX Headlines

Recent News About These Companies

Bank of New York Mellon Corp Purchases Shares of 152,337 4D Molecular Therapeutics, Inc. $FDMT

September 9 at 3:28 AM | marketbeat.com

68,349 Shares in 4D Molecular Therapeutics, Inc. $FDMT Purchased by Man Group plc

September 4, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 6.2% - Time to Sell?

August 31, 2026 | marketbeat.com

BlackRock Inc. Invests $60.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT

August 28, 2026 | marketbeat.com

Trails Edge Capital Partners LP Buys New Stake in 4D Molecular Therapeutics, Inc. $FDMT

August 26, 2026 | marketbeat.com

4DMT to Participate in Upcoming Investor Conferences

August 25, 2026 | globenewswire.com

Parkman Healthcare Partners LLC Acquires New Holdings in 4D Molecular Therapeutics, Inc. $FDMT

August 25, 2026 | marketbeat.com

4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE

August 25, 2026 | marketbeat.com

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

August 24, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7% - Here's What Happened

August 21, 2026 | marketbeat.com

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings

August 18, 2026 | marketbeat.com

146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC

August 18, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,620.00 in Stock

August 18, 2026 | insidertrades.com

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High - Time to Buy?

August 18, 2026 | marketbeat.com

Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

August 17, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

August 17, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10% - Time to Buy?

August 17, 2026 | marketbeat.com

Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT

August 17, 2026 | marketbeat.com

4DMT Announces New Employment Inducement Grants

August 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, DBVT, FDMT, and CTMX Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$8.86 -1.74 (-16.42%)

Closing price 04:00 PM Eastern

Extended Trading

$8.95 +0.09 (+1.06%)

As of 07:55 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CytomX Therapeutics NASDAQ:CTMX

$3.54 -0.11 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$3.54 0.00 (-0.14%)

As of 07:36 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

DBV Technologies NASDAQ:DBVT

$13.44 +0.17 (+1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$13.40 -0.04 (-0.30%)

As of 04:43 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

4D Molecular Therapeutics NASDAQ:FDMT

$14.18 -0.45 (-3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$14.18 0.00 (-0.04%)

As of 07:30 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, DBVT, FDMT, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, DBVT, FDMT, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, DBVT, FDMT, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, DBVT, FDMT, and CTMX Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

CytomX Therapeutics NASDAQ:CTMX

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, DBVT, FDMT, and CTMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, DBVT, FDMT, and CTMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, DBVT, FDMT, and CTMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, DBVT, FDMT, and CTMX Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

CytomX Therapeutics NASDAQ:CTMX

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools